Modulation of arthritis through overexpression of soluble interleukin-1 receptor accessory protein (sIL-1RAcP): A novel inhibitor of interleukin-1, distinct from IL-1Ra

Inflammation Research

Volumn 52, Issue SUPPL., 2003, Pages

  Smeets, R L ^a   Van De Loo, F A J ^a   Joosten, L A B ^a   Arntz, O J ^a   Bennink, M B ^a   Curiel, D T ^b   Martin, M U ^c   Van Den Berg, W B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LUCIFERASE; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; SOLUBLE INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ADENOVIRUS VECTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; SOLUBLE INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN;

ANIMAL MODEL; ARTHRITIS; BIOASSAY; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL TEST; GENE OVEREXPRESSION; MODULATION; MOUSE; NONHUMAN; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DBA 1 MOUSE; DRUG EFFICACY; EXPERIMENTAL ARTHRITIS; IN VITRO STUDY; NONVIRAL GENE THERAPY; SYSTEMIC THERAPY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD;

EID: 0037560320     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Greenfeder SAP et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 1995; 270: 13757-65.
2. Wesche H. et al. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J. Biol. Chem. 1997; 272: 7727-31.
3. Jensen LE et al. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. 2000; 164: 5277-86.
4. Smith DE et al. The Soluble Form of IL-1 Receptor Accessory Protein Enhances the Ability of Soluble Type II IL-1 Receptor to Inhibit IL-1 Action. Immunity. 18.1 2003: 87-96.
5. Joosten LA et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996; 39: 797-809.
6. Chartier C et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J.Virol. 1996; 70: 4805-10.
7. Woole PH et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 1993; 36: 1305-14.
8. Smeets RL et al. The soluble form of the IL-1 Receptor Accessory protein (s1L-1RAcP) is a novel inhibitor of IL-1, effective in collagen-induced arthritis. In Press.
9. Schreuder H et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997; 386: 194-200.